Interleukin Genetics launched a weight management test, and expects web-based tools to further help customers to be available soon. The Weight Management genetic test also includes interpretation of the genetic results from a board-certified, licensed, genetic professional and supplemental guidance on diet types and exercise intensity needed to lose weight and keep it off.
The Weight Management test includes personalized guidance on specific diet and exercise choices that may have the highest impact on weight loss based on the individual’s genetic makeup.
It determines whether an individual is likely to benefit more from a low-fat, low-carbohydrate, or balanced calorie-reduced diet and whether an individual is likely to obtain greater benefit from normal or more vigorous exercise to most efficiently lose weight.
The product was reportedly designed using validated genetic markers involved in fat and carbohydrate absorption, metabolism, and storage.
The Weight Management test is part of Interleukin Genetics’ Inherent Health brand of products. It includes the Periodontal Disease (PST®) Genetic Test, which identifies an individual’s predisposition for tooth loss caused by overexpression of inflammation and subsequent risk for periodontal disease.
The Inherent Health line also includes the Heart Health Genetic Test that identifies a person’s genetic predisposition to heart attack based on inflammation and the Nutritional Needs Genetic Test that identifies DNA variations in genes crucial to B-vitamin metabolism and the ability to manage oxidative stress.
Additionally, the firm expects that its Bone Health Genetic Test will be available during the second half of this year. It is being designed to identify whether an individual is more likely to be susceptible to spine fractures and low bone mineral density associated with osteoporosis.
“We feel the launch of our Inherent Health brand of tests and programs, which focus on wellness and prevention, surpass what has become industry standard for many consumer-focused genetic testing services or products,” remarks Lewis H. Bender, CEO, Interleukin Genetics. “We believe that evidence found through multiple studies linking specific genetic variants to potential negative health outcomes, when coupled with well-packaged and meaningful guidance, can provide consumers with valuable insights to improve their present wellness and future health outcomes.”